UK’s NICE Backs Ruxolitinib Cream for Facial Vitiligo

The National Institute for Health and Care Excellence (NICE) has recommended ruxolitinib cream 15mg/g (Opzelura, Incyte) for routine use in patients in England aged 12 years and older with non-segmental facial vitiligo.

The health technology assessment agency turned down the drug in initial guidance last year. The recent decision follows the publication of the Final Draft Guidance (FDG) for the topical treatment of adults and adolescents with non-segmental vitiligo with facial involvement, according to media reports.

When NICE approves a treatment, it means it is both clinically effective and cost-effective for use within the National Health Service (NHS) in England and Wales, and the NHS is legally obliged to cover the costs.